Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Revenue Recognition · Guidance Revision Potential · Plant 5 Commercialization / 2026-04-23 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [IR] Samsung Electronics (005930) – Q2 2025 Earnings Presentation / 2025-07-31 IR Room
  • [Research] LIG D&A (079550) – Eugene Investment & Securities | Global Demand Spillover · CapEx Expansion · Long-term Compounding / 2026-08-07 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | North American ESS · European LFP Orders · Market Share Expansion / 2026-08-13 Research
  • [Research] LIG D&A (079550) – iM Securities | Premier Air Defense Scarcity · Target Price Upgrade · Global Inquiries / 2026-05-08 Research
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Vessel Margin · FX Gains · Earnings Differentiation / 2026-07-28 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | Capacity Cannibalization · 1-Year LTA · Pricing Power / 2026-07-06 Research

[Research] SK hynix (000660 / SKHY) – DS Investment | Memory ASP · High-Value Product Mix · Supply Tightness / 2026-04-23

Posted on April 23, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : DS Investment & Securities

Analyst : Surim Lee

Investment Rating : BUY (Maintained)

Target Price : 1,600,000 KRW (Upgraded)

Core Momentum : Sharp DRAM and NAND ASP increases and a richer high-value product mix are expected to drive continued earnings upgrades, while constrained wafer input growth keeps memory supply tight through 2027.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price / Investment Rating: 1,600,000 KRW / BUY
  • Current Price (as of 04/22): 1,223,000 KRW (Upside potential: 30.8%)
  • Market Capitalization: 871,635 billion KRW (Common stock)
  • Key Financial Metrics (2025A / 2026F / 2027F):
    • Revenue: 97,147 billion KRW / 306,708 billion KRW / 405,280 billion KRW
    • Operating Profit: 47,206 billion KRW / 223,489 billion KRW / 298,574 billion KRW
    • Operating Margin: 48.6% / 72.9% / 73.7%
    • Net Income Attributable to Controlling Interests: 37,427 billion KRW / 181,435 billion KRW / 242,662 billion KRW
    • EPS: 51,410 KRW / 249,223 KRW / 333,326 KRW
    • ROE: 41.0% / 91.4% / 59.3%
    • PER: 10.1x / 4.9x / 3.7x
    • PBR: 3.5x / 3.1x / 1.7x

🚀 2. [Market Opportunities & Business Outlook]

  • 1Q26 Performance Summary: 1Q26 revenue reached 52.6 trillion KRW (+60% QoQ) and operating profit recorded 37.6 trillion KRW (+96% QoQ, OPM 72%), slightly missing consensus on revenue but beating expectations on operating margin.
  • ASP and Bit Growth Trends: Driven by high-value product expansion, DRAM ASP increased 65% QoQ and NAND ASP jumped 74% QoQ, significantly outperforming expectations. Bit growth (B/G) stood at +0.3% QoQ for DRAM and -13% QoQ for NAND, affected by base effects from the previous quarter, reduced retail sales, and longer production lead times. Operating margins were 78% for DRAM and 49% for NAND.
  • Supply and Production Outlook: While wafer input is expected to grow only in the single digits this year, production B/G will meaningfully increase via tech migrations, keeping supply conditions tight through 2027. Solidigm Dalian Phase 2 capacity expansion is resuming, and over 50% of domestic capacity is planned to transition to 321-layer nodes by year-end.
  • Earnings Forecast Upgrades: Projected operating profit for 2Q26 has been revised upward to 56 trillion KRW (+50% QoQ, OPM 73%). Full-year operating profit forecasts are upgraded to 223 trillion KRW (+373% YoY, OPM 73%) for 2026 and 299 trillion KRW (+34% YoY, OPM 74%) for 2027.
  • Shareholder Return & Other Catalysts: Additional shareholder return plans, including share buybacks and cancellations alongside dividends, are under active review for execution within the year. Preparations for an ADR listing in the U.S. market are underway, providing further momentum on the supply-demand front in the second half.

📝 Editor’s Comment (Perspective)

The analyst evaluates that substantial ASP surges and high-value product expansion in both DRAM and NAND are directly driving earnings upgrades, while tight supply conditions are expected to persist through 2027 amid constrained wafer input growth and tech migration-driven production responses. This perspective focuses on earnings growth momentum derived from price increases and enriched product mix rather than short-term shipment fluctuations.

To determine whether this investment thesis is unfolding as projected, key items to monitor include whether the upward trends in DRAM and NAND ASPs alongside product mix improvements translate into the projected 56 trillion KRW operating profit for Q2 and full-year earnings, as well as whether tight supply conditions are sustained under limited wafer input growth. These developments can be tracked through upcoming quarterly and annual earnings releases, official corporate IR materials, and regulatory disclosures via DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Yuanta | Memory Pricing · Long-Term Contracts · Earnings Stability / 2026-04-23
Next Post: [Research] SK hynix (000660 / SKHY) – Meritz | ADR Listing · Valuation Discount · Re-rating / 2026-04-23

Related Posts

  • [Research] Samsung SDI (006400) – iM Securities | ESS Business Pivot · AMPC Benefits · Earnings Visibility / 2026-07-31 Research
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Order Recovery · Plant Ramp-up · Earnings Growth / 2026-07-24 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 2Q26 Review · Backlog Realization · Export Margin Expansion / 2026-08-10 Research
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Plant 5 Revenue Contribution · US Plant Acquisition · Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Acquisition Finalized · Guidance Revision Outlook · Tariff Resilience / 2026-04-02 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research
  • [Research] SK hynix (000660 / SKHY) – Yuanta | Memory Pricing · Long-Term Contracts · Earnings Stability / 2026-04-23 Research
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Plant 5 Revenue Contribution · US Plant Acquisition · Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | Supply Shortage · High-End Mix · Earnings Upward Cycle / 2026-07-31 Research
  • [Research] Samsung Biologics (207940) – Kyobo Securities | H2 Revenue Recognition · Modality Diversification · Earnings Growth / 2026-07-24 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2023 Earnings Presentation / 2024-01-31 IR Room
  • [Research] Celltrion (068270) – DS Investment & Securities | 2nd-Gen Biosimilar Penetration · COGS Ratio Stabilization · Global Capacity Expansion / 2026-05-07 Research
  • About Korea Equity Lens & Privacy Policy About
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme